Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Gains from Sales and Divestitures (2017)

Cytokinetics (CYTK) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $171250.0 as the latest value for Q4 2017.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $171250.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $171250.0, a N/A change, with the full-year FY2017 number at $171250.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $171250.0 for Q4 2017 at Cytokinetics, up from $20833.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $211897.0 in Q3 2013 to a low of $20833.0 in Q4 2014.
  • A 3-year average of $153969.2 and a median of $191573.5 in 2013 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 115.23% in 2013, then crashed 90.17% in 2014.
  • Cytokinetics' Gains from Sales and Divestitures stood at $211897.0 in 2013, then plummeted by 90.17% to $20833.0 in 2014, then skyrocketed by 722.01% to $171250.0 in 2017.
  • Per Business Quant, the three most recent readings for CYTK's Gains from Sales and Divestitures are $171250.0 (Q4 2017), $20833.0 (Q4 2014), and $211897.0 (Q4 2013).